stimulant. The ongoing stimulation via a substitute lectin could account for the ongoing somatic mutation. Our data support the concept that glycosylation could contribute to the development of FL. The characteristic t(14;18) chromosomal translocation may be only a first step to tumorigenesis, and we propose that the universal acquisition of N-glycosylation sites in the GC contributes a second critical factor. The nature of the added oligosaccharide is at present under investigation, with preliminary experiments suggesting an unusual composition (manuscript in preparation). If this is indeed a mechanism required for maintenance of FL, interruption would provide a clear therapeutic goal. 
Several groups have recently reported the presence of a unique gain-of-function JAK2 point mutation (V617F) in the majority of cases of classic cMPD as well as in a minority of atypical MPDs and in occasional cases of AML. To date, this mutation has not been reported in normal controls, lymphoid disorders or in patients with secondary erythrocytosis. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] In this study, we have analyzed bone marrow or peripheral blood samples from 349 patients (PV, n ¼ 84; ET, n ¼ 243; IMF, n ¼ 22) referred to our diagnostic service for cytogenetic analysis and/or exclusion of the BCR-ABL fusion from several hospitals in the north of Spain between 1996 and 2005. Our study group thus includes the largest series of ET cases reported to date for JAK2 analysis. DNA was extracted and tested for V617F by a sensitive amplification refractory mutation system as described previously. 6 Results were obtained from all samples and V617F was detected in 80, 62 and 68% of cases of PV, ET and IMF, respectively (Table 1) . These frequencies are comparable to other studies for PV and IMF, but somewhat higher than expected for ET, for which 23-57% of cases have been reported as V617F positive. Part of the reason for this is probably attributable to technical differences in the sensitivity of the V617F detection. Most other studies used sequencing, which can underestimate the proportion of positive patients, 2, 6 whereas allele-specific PCR assay is capable of detecting a mutation present in 1-2% of cells. 6 Of the 17 V617F-negative PV cases of our series, only two were female (P ¼ 0.044, contingency w 2 ¼ 4.058). This supports the previous observation of a significant male excess in mutation-negative PV cases. 6 In addition, a relative risk ratio estimate (RR ¼ 1.26; confidence interval 95% ¼ 1.04-1.52) of our data indicated that V617F is 26% more frequent in PV females compared to PV males (Table 1) .
PV and IMF are both considered to be clonal diseases, but for ET only approximately half of the cases are clonal, the remainder being polyclonal and therefore presumably reactive. It has been suggested 6 that the great majority of clonal ET cases must be V617F positive, but it remains to be determined if any V617F ET cases are also clonal. To address this question, we compared karyotypes between mutation-negative and mutationpositive cases. Of the 191 ET cases for whom cytogenetic analysis had been successfully performed, clonal cytogenetic abnormalities were observed in 11 of the 118 (9%) V617F-positive and five of the 73 (7%) V617F-negative patients ( Table 2) . Although the frequency of chromosome abnormalities is lower in V617F-negative ET cases, these data show that at least some of these cases are indeed clonal.
Karyotypes were also available for 79 of the 85 PV patients (V617F positive, n ¼ 62; V617F negative, n ¼ 17) and 19 of the 22 IMF cases (V617F positive, n ¼ 12; V617F negative, n ¼ 7) ( Table 2 ). For PV, 11 V617F-positive patients had cytogenetic abnormalities, of which three showed del(20q), four showed þ 9 and four had ÀY or þ 8. A single V617F-negative PV patient was karyotypically abnormal with del(20q). For IMF patients, all of V617F-positive cases had a normal karyotype, whereas two of the negative V617F patients showed aberrations (Table 2) .
Thus, on the basis of cytogenetics, it is clear that some V617F-negative cMPD cases have a clonal disease, suggesting the existence of uncharacterized mutation/s that may or may not lie in the same signal transduction pathway. Currently, it is not clear if JAK2 V617F is the initiating, disease-causing mutation or an important secondary event. However, our finding of known recurrent cytogenetic abnormalities in both V617F-positive and -negative cases supports the notion that the development of cMPDs is a multistep pathogenetic process. Genetics Division, University of Southampton, Southampton, UK E-mail: jlvizmanos@unav.es The number of metaphases are between brackets. 
